Top View
- Study Protocol-Related Adverse Event Should Be Recorded from the Time of Informed Consent
- Progress in Targeted Alpha-Particle Therapy. What We Learned About Recoils Release from in Vivo Generators
- INN Working Document 05.179 Update 2011
- Novel Drugs for Older Patients with Acute Myeloid Leukemia
- Immunoconjugates Advances in the Treatment of Hematologic
- Actinium Pharmaceuticals Highlights Strong Presence at 59Th Annual
- IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
- 2018 Medicines in Development for Cancer
- (INN) for Biological and Biotechnological Substances
- Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications
- Actinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted
- Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats
- Development of Therapeutic Antibody Technology and Recent
- Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
- View Annual Report
- RIT): Moving Forward Jordan M
- Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody
- Targeted Alpha-Particle Therapy for Acute Myeloid Leukemia
- Acute Leukemia – from Precision Medicine to Immunorx
- Emerging Therapies for Acute Myeloid Leukemia: Translating Biology Into the Clinic
- Supplementary Tables and Figures Section 1. Distribution of CDR-H3
- Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M
- In Vitro and in Vivo Efficacy of a Novel CD33 Targeted Thorium-227 Conjugate for The
- WO 2016/001485 Al 7 January 2016 (07.01.2016) P O P C T
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- Novel Monoclonal Antibody-Based Therapies for Acute Myeloid Leukemia T
- A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytara
- Radioimmunotherapy of Human Tumours
- 761060Orig1s000 761060Orig2s000
- Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
- (INN) for Biological and Biotechnological Substances
- Radiopharmaceutical Therapy in Cancer: Clinical Advances and Challenges
- In Vitro and in Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
- View Annual Report
- Panitumumab Modified with Metal Chelating Polymers (Mcps) Complexing Indium‐111 and Lutetium-177 As Theranostics for Pancreatic Cancer
- Assessment of the Evolution of Cancer Treatment Therapies
- Federal Register/Vol. 64, No. 13/Thursday, January 21, 1999/Notices
- Oncology Drugs in the Pipeline
- Alpha Emitters for Radiotherapy: Basic Radiochemistry to Clinical Studies – Part 2
- CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
- AML in Adult Patients -Presentation